![Erica Kratz](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Erica Kratz
General Counsel bei
AURA BIOSCIENCES, INC.
Vermögen: 619 434 $ am 31.10.2026
Profil
Erica Kratz is Chief Regulatory & Quality Officer at Aura Biosciences, Inc. since 2026.
Formerly, Dr. Kratz was Vice President-Regulatory at Denali Therapeutics, Inc. from 2022 to 2026.
Education includes undergraduate studies at the University of Arizona and a doctorate from the University of California.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.09.2026 | 100’885 ( 0.1% ) | 619 434 $ | 31.10.2026 |
Aktive Positionen von Erica Kratz
| Unternehmen | Position | Beginn |
|---|---|---|
| AURA BIOSCIENCES, INC. | General Counsel | 11.08.2026 |
Ehemalige bekannte Positionen von Erica Kratz
| Unternehmen | Position | Ende |
|---|---|---|
| DENALI THERAPEUTICS INC. | General Counsel | 01.05.2026 |
Ausbildung von Erica Kratz
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
34
Beziehungen ersten Grades
4
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Aura Biosciences, Inc.
 Aura Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company leveraging novel targeted oncology platform to develop new standard of care across multiple cancer indications | Health Technology |
University of Arizona
 University of Arizona Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California
 University of California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Denali Therapeutics, Inc.
 Denali Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapeutics for neurodegenerative diseases | Health Technology |
